ClinicalTrials.gg
RecruitingNCT07509775Updated Apr 9, 2026

Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis (AS): A Cohort Study Protocol Focusing on Spondyloarthritis Research Consortium of Canada (SPARCC) Scoring System

An observational study in Ankylosing Spondylitis (AS), sponsored by China-Japan Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by China-Japan Friendship Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
210
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Spondylitis, Ankylosing with a site in China — 20 open to participants now, 23 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.

Planned enrollment
10th of 15
210 · median 400
Started
2026
with 7 others
Observational
15 of 77
7 open now
Primary completion
2027-12
later than 15 of 22 live
Registered
69th of 77
by date
Lead sponsor
4 of 77
China-Japan Friendship Hospital

Among the 77 studies in Spondylitis, Ankylosing with a site in China, this one is the 10th largest by planned enrollment of the 15 observational ones that give a count, is one of 8 that started in 2026, is one of 15 observational ones, reaches primary completion later than 15 of the 22 other live ones, and was the 69th registered.

Spondylitis, Ankylosing

535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

20 of the 77 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 24 (38%) set no upper age limit and 33 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Spondylitis, Ankylosing with a site in China, or all of them as a file.
02

Study summary

This study is a multicentre, ambidirectional, observational cohort study. The ambidirectional design incorporates both the collection of retrospective data from the three years prior to enrolment, and a prospective follow-up period of up to two years. The study is designed to evaluate the long-term effects of Integrated Medicine on radiographic progression in patients diagnosed with Ankylosing spondylitis (AS).

03

Conditions studied

  • Ankylosing Spondylitis (AS)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with Ankylosing spondylitis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • fulfill the 1984 modified New York criteria for ankylosing spondylitis or the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial spondyloarthritis
  • age between 18 and 75 years
  • sign .

Exclusion criteria

Exclusion Criteria:

  • diagnosis of other diseases besides the disease under investigation (e.g., rheumatoid arthritis, Sjögren's syndrome, erythema nodosum, myositis, etc.)
  • pregnancy or lactation
  • comorbid severe cardiovascular or cerebrovascular diseases, hepatic or renal failure, or
  • spondyloarthritis related to enteropathic arthritis, psoriatic arthritis, or reactive arthritis
  • unable to provide data due to mental, language, or similar factors.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
210 participants (estimated)
Patient registry
No

Groups and cohorts

  • exposed group

    Participants who receive traditional Chinese medicine (TCM) therapy for more than 60% of the total duration of their prospective follow-up period.

  • non-exposed group

    Participants who do not receive any TCM therapy.

06

What researchers measure

Primary outcomes

  1. The change in Spondyloarthritis Research Consortium of Canada (SPARCC) scores from baseline to 12 months

    The primary outcome measure assesses the changes in spinal inflammation following one year of Integrated Traditional Chinese and Western Medicine (Integrated Medicine) treatment. Select six consecutive vertebral units showing the most pronounced oedema (each unit comprising the vertebral body and the two inferior vertebral angles) for scoring; the total score ranges from 0 to 30 points. A reduction in the total score before and after treatment (e.g. from 20 to 8 points) indicates that the inflammation has been effectively controlled.

    Time frame: Review the imaging data from up to three years prior to enrolment and assessed annually in the two-year follow-up period ahead.

Secondary outcomes

  1. The change in SPARCC scores from baseline to 24 months

    The change in SPARCC scores from baseline to 24 months, which is added to evaluate the longer-term durability of the treatment effect and to capture potential continued improvement or late-onset changes in spinal inflammation beyond the first year.

    Time frame: Review the imaging data from up to three years prior to enrolment and assessed at baseline and 24 months.

  2. The longitudinal progression of spinal inflammation

    We will use the trajectory of SPARCC score changes at baseline, 12 months, and 24 months during the prospective follow-up to evaluate the longitudinal progression of spinal inflammatory lesions.

    Time frame: Assessed annually in the two-year follow-up period ahead.

  3. The Bath Ankylosing Spondylitis Functional Index (BASFI)

    To define and monitor physical functioning in patients with ankylosing spondylitis (AS). Score range is 0 - 10, with 0 reflecting no functional impairments and 10 reflecting maximal impairment.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  4. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),

    To measure patient-reported disease activity in patients with ankylosing spondylitis (AS). Score ranges from 0 (no disease activity) to 10 (maximal disease activity). A cut off of 4 is used to define active disease. High disease activity: BASDAI ≥ 4; low disease activity: \< 4.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  5. The Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP)

    To measure disease activity in ankylosing spondylitis (AS) based on a composite score of domains relevant to patients and clinicians, including both self-reported items and objective measures. Score ranges from 0 (reflecting no disease activity) with the upper end of the scale being determined by the level of the CRP. It defined 4 important disease states: inactive disease, moderate, high, and very high disease activity, and relevant cut offs between these states were 1.3, 2.1, and 3.5 units, respectively. Clinically important improvement was found to be 1.1 units or greater and major improvement was defined as a change of 2.0 units or more.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  6. The Bath Ankylosing Spondylitis Metrology Index (BASMI)

    To quantify the mobility of the axial skeleton in ankylosing spondylitis (AS) patients and allow objective assessment of clinically significant changes in spinal movement. Score ranges from 0 to 10. A lower score indicates better mobility of the spine and hips, and less severe structural damage. A higher score indicates more severe joint ankylosis and restricted movement, and that the disease has caused significant structural consequences.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  7. The Ankylosing Spondylitis Quality of Life Scale(ASQoL)

    To measure the impact of ankylosing spondylitis (AS) on health-related quality of life from the patient's perspective. Score range is 0-18. The score directly reflects the extent to which quality of life has been impaired; the lower the score, the better the quality of life has been maintained; conversely, the higher the score, the more severe the negative impact of the illness on quality of life.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  8. The Visual Analogue Scale (VAS)

    To reflect the level of pain. Pain intensity is rated on a scale of 0 to 10. 0: no pain/absolutely none; 10: the most severe pain/unbearable, extreme discomfort.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  9. Inflammatory marker: the serum C-reactive protein (CRP) levels

    To monitor systemic inflammation and disease activity in patients with ankylosing spondylitis (AS).

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  10. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    AEs and SAEs including gastrointestinal reactions, abnormal liver and kidney function, and cardiovascular events. These conditions are monitored based on symptoms reported by patients, as well as routine blood and urine tests, faecal occult blood tests, liver and kidney function tests, and electrocardiograms.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  11. Treatment adherence

    Treatment adherence is assessed based on the use of traditional Chinese medicine (TCM) and Western medicine during the two-year follow-up period.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  12. Time to discontinuation of Western medication

    The time period from the first dose of Western treatment to the permanent discontinuation of any Western medicine (including non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs)) for ankylosing spondylitis (AS).

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  13. The use of non-steroidal anti-inflammatory drugs (NSAIDs)

    To assess the use of non-steroidal anti-inflammatory drugs (NSAIDs) by participants during the study period.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

Of 47 non-industry observational studies under Spondylitis, Ankylosing, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 201. This study's planned 23 months is below that.

Counting every sponsor, half of 80 studies reached it within 47 months; a quarter within 27 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Apr 3, 2026
StartActual
Jan 19, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07509775
Collaborators
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, Guangxi Ruikang Hospital, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Beijing Electric Power Hospital, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Xi'an Fifth Hospital, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital
Responsible party
Qingwen Tao (Chief physician, China-Japan Friendship Hospital) — Principal investigator
First posted
Apr 3, 2026
Start date
Jan 19, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Apr 9, 2026

Study contacts

Yuanyuan Zou, Doctor
Contact
zyysdmn1234@163.com
+86 18080935783

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion